Clinical Trials Logo

Leukoplakia, Oral clinical trials

View clinical trials related to Leukoplakia, Oral.

Filter by:

NCT ID: NCT00369174 Completed - Oral Leukoplakia Clinical Trials

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia

NCT ID: NCT00330382 Completed - Clinical trials for Oropharyngeal Cancer

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

Start date: January 1999
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well Bowman-Birk inhibitor concentrate works in preventing cancer in patients with oral leukoplakia. Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate, a substance made from soy, may keep cancer from forming in patients with oral leukoplakia

NCT ID: NCT00299195 Completed - Leukoplakia, Oral Clinical Trials

A Randomized Study of Sulindac in Oral Premalignant Lesions

Start date: February 23, 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people with arthritis (inflammation of a joint). This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer Centre (RCC) in Trivandrum, India.

NCT ID: NCT00155337 Completed - Oral Leukoplakia Clinical Trials

Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Photodynamic therapy for oral leukoplakia and erythroleukoplakia

NCT ID: NCT00101335 Completed - Clinical trials for Head and Neck Cancer

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Start date: November 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.

NCT ID: NCT00099021 Completed - Clinical trials for Head and Neck Cancer

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Start date: June 2003
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be effective in preventing head and neck cancer.